Stimulator of Interferon Genes-Activated Biomimetic Dendritic Cell Nanovaccine as a Chemotherapeutic Booster to Enhance Systemic Fibrosarcoma Treatment-Reference-Cited by-同舟云学术

Stimulator of Interferon Genes-Activated Biomimetic Dendritic Cell Nanovaccine as a Chemotherapeutic Booster to Enhance Systemic Fibrosarcoma Treatment

Published:2024-08-22 Issue:35 Volume:18 Page:24219-24235
ISSN:1936-0851
Container-title:ACS Nano
language:en
Short-container-title:ACS Nano

Author:

Wang Zhao¹,Miao Fenglin²,Gu Lingwei²,Zhang Ruyi²,Ma Yuan²,Li Ying³,Zheng Jialiang²,Lin Zhenhang²,Gao Yilai²,Huang Liyong⁴,Shen Ye⁵,Wu Ting⁶^ORCID,Luo Fanghong⁶^ORCID,Li Wengang¹^ORCID

Affiliation:

1. Department of Hepatobiliary Surgery, Xiang’an Hospital of Xiamen University, Cancer Research Center, School of Medicine, Xiamen University, Xiamen 361102, Fujian, China

2. Cancer Research Center, Xiang’an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361000, Fujian, China

3. Heji Hospital Affiliated with Changzhi Medical College, Changzhi 046000, Shanxi, China

4. Fuzhou No. 1 Hospital Affiliated with Fujian Medical University, Fuzhou 350000, Fu Jian, China

5. Shanghai Jiangxia Blood Technology Co., Ltd. Shanghai 200000, China

6. Cancer Research Center, School of Medicine, Xiamen University, Xiamen 361102, Fujian, China

Funder

Natural Science Foundation of Fujian Province

National Natural Science Foundation of China

Joint research center of School of Medicine, Xiamen University-Jiangsu Charity Biotech Co. Ltd

Joint laboratory of School of Medicine, Xiamen University-Shanghai Jiangxia Blood Technology Co. Ltd

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsnano.4c05657

Reference45 articles.

1. Integrated genetic and epigenetic analysis of myxofibrosarcoma

2. Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival

3. Adult Soft-Tissue Sarcomas of the Extremities

4. Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine

5. Current diagnostics and treatment of fibrosarcoma -perspectives for future therapeutic targets and strategies